Clinical Trials on Breast Cancer Metastatic in Japan

Total 1268 results

Eisai Co., Ltd.

Completed

Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

Inoperable or Recurrent Breast Cancer

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 2 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 3 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Novartis Pharmaceuticals

Completed

Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer

NON-breast HER2+ Malignancies

United States, Italy, Korea, Republic of, Japan
ETOP IBCSG Partners Foundation
Breast International Group

Completed

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer (SOLE)

Breast Cancer

France, Spain, Switzerland, Australia, Belgium, Austria, Peru, Germany, Italy, Japan, New Zealand, Sweden, Denmark, India, United States, Chile, Russian Federation, United Kingdom, Hungary, South Africa
Tomoshi Tsuchiya

Completed

A Feasibility Study of Oral Adjuvant Chemotherapy With S-1

Non-small Cell Lung Cancer

Japan
Hamamatsu University

Completed

Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Japan
AstraZeneca

Terminated

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer (MINT)

Neoplasms | Breast Cancer | Breast Neoplasms

Brazil, Czech Republic, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, South Africa, United Kingdom, Philippines, Ukraine, Finland, Canada, Taiwan, India, Thailand, United States, Japan
Shizuoka Cancer Center

Unknown

Phase II Study for Robot Assisted Distal Gastrectomy (RADGphaseII)

Early Gastric Cancer

Japan
Novartis Pharmaceuticals

Completed

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein

Taiwan, Switzerland, Korea, Republic of, Germany, United States, Japan
Bayer

Completed

A Study to Learn More About What Japanese Patients With Solid Tumors Think About Taking Medicine That is Based on Their Genetic Information

Cancer Genomic Profiling

Japan
Pfizer

Terminated

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Korea, Republic of, United States, Japan, Spain
Taiho Oncology, Inc.

Active, not recruiting

Futibatinib in Patients With Specific FGFR Aberrations

Advanced or Metastatic Solid Tumor | Advanced or Metastatic Gastric or Gastroesophageal Cancer | Myeloid or Lymphoid Neoplasms (MLN)

United States, Spain, Turkey, Hong Kong, Korea, Republic of, Belgium, Japan, Netherlands, France, Germany, Italy, Sweden, United Kingdom, Portugal, Singapore
Osaka University
Ono Pharmaceutical Co. Ltd; Kyowa Kirin Co., Ltd.; Clinical Study Support, Inc.; Fiverings Co., Ltd...

Completed

Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients

Gastric Cancer | Esophageal Cancer | Lung Cancer | Renal Cancer | Oral Cancer

Japan
Taro Iguchi, MD, PHD
Astellas Pharma Inc

Completed

Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.

Castration-resistant Prostate Cancer

Japan
AstraZeneca
Daiichi Sankyo

Active, not recruiting

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Breast Cancer

Belgium, Canada, France, Italy, Spain, United Kingdom, Hungary, Poland, United States, Korea, Republic of, Brazil, India, Japan, Russian Federation, China, Taiwan, Netherlands, Germany, South Africa, Argentina
Novartis Pharmaceuticals

Completed

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation (BELLE-4)

Breast Cancer

Belgium, France, Taiwan, Hungary, Germany, Singapore, Austria, Netherlands, Australia, Russian Federation, Spain, Canada, Israel, Japan, Korea, Republic of, Italy, United States, United Kingdom, Brazil, Hong Kong, Czech Republic, South...
Novartis Pharmaceuticals

Active, not recruiting

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Advanced Solid Tumors | Triple Negative Breast Cancer | Chordoma and Alveolar Soft Part Sarcoma

United States, Taiwan, Spain, Canada, Singapore, Italy, Japan, Israel, France
Bristol-Myers Squibb

Completed

Phase 1 Study of Mesothelin-ADC

Advanced Cancer

Japan
Novartis Pharmaceuticals

Completed

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO-1)

Breast Cancer

China, United States, France, Italy, United Kingdom, Taiwan, Turkey, Egypt, Germany, Hong Kong, Belgium, Canada, Russian Federation, Lebanon, Japan, Australia, Greece, Korea, Republic of, Ireland, Peru, Argentina, Brazil, Colombia, South... and more
Hoffmann-La Roche
European Organisation for Research and Treatment of Cancer - EORTC; NCIC Clinical... and other collaborators

Completed

Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer (HERA)

Breast Cancer

France, Spain, Switzerland, Greece, Italy, Korea, Republic of, Australia, Canada, Poland, Belgium, United Kingdom, Netherlands, Germany, Chile, Ireland, Portugal, South Africa, Sweden, China, Austria, Hungary, Brazil, Colombia, Thailand, Denma... and more
Eisai Co., Ltd.

Completed

A Study of E7080 in Subjects With Solid Tumor

Cancer

Japan
Fukushima Medical University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Bristol-Myers Squibb

Completed

Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors

Cancer

Japan
Epidemiological and Clinical Research Information...

Completed

A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC (AXEPT)

Gastrointestinal Neoplasms | Digestive System Neoplasms | Neoplasm Metastasis | Colorectal Neoplasms | Intestinal Neoplasms

Japan
Translational Research Center for Medical Innovation...
Tokyo Medical and Dental University

Completed

Study of Tumor Samples From Patients With Stage III Colon Cancer Who Have Undergone Surgery and Chemotherapy

Colorectal Cancer

Japan
Tokyo University
Shionogi; National Cancer Center Hospital East; Hokkaido University; Fukushima... and other collaborators

Unknown

Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer

Non-small- Cell Lung Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of ARQ 197 in Combination With Erlotinib

Advanced/Recurrent Non-small-cell Lung Cancer

Japan
Eli Lilly and Company

Completed

A Study of LY2584702 in Solid Tumors

Cancer

Japan
Bayer
Onyx Therapeutics, Inc.

Completed

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Breast Cancer

Spain, Ireland, Japan, Russian Federation, United States, Australia, Austria, Czechia, Belgium, China, Germany, Hungary, Israel, South Africa, United Kingdom, France, Greece, Puerto Rico, Italy, Canada, Poland, Sweden, Argentina
Kyowa Kirin Co., Ltd.

Terminated

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib (ATTENTION)

Non-small-cell Lung Cancer

Japan
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Unknown

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Gunma University
J~pharma

Completed

Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer

Non-Small Cell Lung Cancer

Japan
AstraZeneca
MedImmune LLC

Completed

Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects

Cancer | Advanced Solid Malignancies

Japan
Wakayama Medical University
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

Japan
Clinical Research Support Center Kyush

Unknown

Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)

Rectal Cancer

Japan
Pfizer

Active, not recruiting

A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Neoplasms | Breast Neoplasms

Japan
Bristol-Myers Squibb

Completed

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Advanced Cancer

Japan
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Breast Cancer

China, United States, Spain, Hungary, Israel, Korea, Republic of, Taiwan, Belgium, Austria, Russian Federation, Switzerland, Portugal, France, Canada, Italy, United Kingdom, Greece, Japan, Germany, Sweden
Novartis Pharmaceuticals

Completed

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (BOLERO-2)

Breast Cancer

United States, Belgium, Canada, France, Spain, Turkey, Japan, Egypt, Germany, Austria, Poland, Sweden, United Kingdom, Thailand, Hungary, Australia, Italy, Netherlands, Brazil, Hong Kong, Czech Republic, Korea, Republic of, New Zealand and more
Takeda

Recruiting

Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd; Nektar Therapeutics

Completed

An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

Advanced Cancer

Japan
Sanofi

Terminated

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (AMEERA-5)

Breast Cancer

United States, Russian Federation, Italy, Australia, Belgium, France, Japan, Ukraine, Netherlands, Argentina, Canada, Portugal, Spain, Austria, Brazil, Bulgaria, Chile, China, Czechia, Finland, Georgia, Germany, Hungary, Korea, Republic... and more
Novartis Pharmaceuticals

Completed

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1)

Breast Cancer

United States, France, Spain, United Kingdom, Austria, Germany, Taiwan, Australia, Italy, Israel, Russian Federation, Korea, Republic of, Hong Kong, Thailand, Canada, Hungary, Japan, Lebanon, Belgium, Bulgaria, Greece, Argentina, Peru, Czech... and more
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Breast Cancer

United States, France, Czechia, Italy, Korea, Republic of, Australia, Belgium, Brazil, Canada, Germany, Guatemala, Hong Kong, Hungary, Panama, Peru, Poland, Spain, Taiwan, United Kingdom, Colombia, Bosnia and Herzegovina, Chile, El... and more
Wakayama Medical University

Completed

Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy

Pancreatic Cancer | Bile Duct Cancer | Pancreatitis | Duodenal Cancer | Ampullary Cancer

Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Real-World Evidence and Treatment Patterns: Head and Neck Cancer

Head & Neck Cancer

Japan
National Cancer Center, Japan
Ono Pharmaceutical Co. Ltd; Fiverings Co., Ltd.

Completed

A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

Gastric Cancer | Gastroesophageal Junction Region (GEJ) Cancer

Japan

Clinical Trials on Breast Cancer Metastatic in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations